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Introduction: The value of a nonanthracyclin regimen in thymic
carcinoma and malignant thymoma is not well defined. These
regimens may be useful in some patients, particularly with cardiac
diseases. The objective of this study is to evaluate the response rate,
progression free survival, overall survival and toxicity of combined
etoposide, ifosfamide, and cisplatin in patients with advanced thy-
moma and thymic carcinoma.
Methods: From October 1995 to April 2001, 18 patients with
advanced thymoma or thymic carcinoma were entered on trial, and
receive etoposide (100 mg/m2 on days 1–3), ifosfamide (1500
mg/m2 on days 1–3), s and cisplatin (30 mg/m2 on days 1–3). Cycles
were repeated every 3 weeks for a total of six cycles.
Results: Among 16 evaluable patients, there were no complete
responses and four partial responses (complete and partial responses
rate, 25%; confidence interval [CI] 95, 7–48%). The median fol-
low-up was 32.6 months (range, 9–84 months), and the median
overall survival has not yet been reached because more than 50% of
patients are still alive. Based on Kaplan-Meier estimates, the 1-year
and 2-year survival rates were 93.8 and 78.1%, respectively. The
toxicity was predominantly myelosuppresion and alopecia.
Conclusions: The combined etoposide, ifosfamide, and cisplatin
regimen has moderate activity in patients with advanced thymic
tumors. Our results confirm the Eastern Cooperative Oncology
Group trial published in 2001. Response rates appear to be lower to
many phase II trials, but survival seems similar.
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Epithelial thymic tumors, including thymoma and thymiccarcinoma are rare tumors, but they represent the most
common tumor of the anterior mediastinum.1 Most of them
are discovered on routine chest radiographs or during evalu-
ation for myasthenia gravis. In this situation, they are often
well encapsulated and are easily removed by surgical exci-
sion. Less frequently (about 30%), patients present with an
advanced disease or a recurrence after primary therapy.2
These cases need chemotherapy, alone or in combination
with surgery and/or radiotherapy.3
Because of rarity of these tumors, the published trials
with chemotherapy have been limited, but several retrospec-
tive experiences and prospective trials have demonstrated
their chemotherapy ssensitivity. Data regarding thymic car-
cinoma are even more scant and suggest a lesser sensitivity to
chemotherapy.
Several drugs, alone or in combination, can produce
objective responses (OR) in advanced thymic tumors. The
most commons agents in this setting are cisplatin, doxorubi-
cin, cyclophosphamide, ifosfamide, and etoposide.4 Several
prospective trials have confirmed objective response rates
from 50 to 90% using cisplatin-based combination chemo-
therapy regimens.5 Two prospective trials in the United States
have combined cisplatin, doxorubicin, and cyclophospha-
mide (PAC): the response rate in patients with advanced
disease was 50 and 70% in those with limited stage.6,7 The
European Organization for Research in the Treatment of
Cancer reported a prospective multicentric trial using cis-
platin (60 mg/m2 on day 1) and etoposide (120 mg/m2 on
days 1–3) administered every 3 weeks for six courses in
patients with metastatic or recurrent thymoma. Patients did
not receive corticosteroids. Sixteen patients were evalu-
able, five presented a complete response (CR), four pre-
sented a partial response (PR), which represents a 56%
objective response rate. The median duration of response
was 3.4 years (range, 4 –78 months), the median time to
progression was 2.2 years, and the median survival time
was 4.3 years.8 Highley et al.9 reported a prospective trial
with 13 patients with thymoma and thymic carcinoma
treated with ifosfamide alone: five patients presented a CR
and one a PR. The two patients with thymic carcinoma did
not respond to ifosfamide.
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On the basis of these data and to test the value of a
nonanthracyclin regimen (which could avoid cardiac toxic-
ity), Loehrer et al reported an Eastern Cooperative Oncology
Group (ECOG) trial with 34 patients with advanced or
recurrent thymoma and thymic carcinoma treated with the
combined etoposide, ifosfamide, and cisplatin (VIP) regimen.
Patients received four courses every 3 weeks with etoposide
(75 mg/m2 on days 1–4), ifosfamide (1200 mg/m2 on days
1–4), and cisplatin (20 mg/m2 on days 1–4). Twenty-eight
patients were evaluable: nine PR and no CR were observed
(OR  32%). The median duration of response was 11.9
months (range, 1–26 months), the median overall survival
was 31.6 months. Based on Kaplan-Meier estimates, the
1-year and 2-year survival rates were 89 and 70%, respec-
tively. The toxicity was predominantly myelosuppression.
These results suggested moderate activity of the VIP regimen
in patients with advanced thymic malignancies.10,11
At the same time, The Gustave Roussy Institute initi-
ated a phase II trial to evaluate the response rate, progression
free survival, overall survival, and toxicity of the VIP regi-
men in advanced thymic tumors. Here, we report the results
of these phase II trial.
PATIENTS AND METHODS
Study Population
From October 1995 to April 2001, 18 patients were
entered on study. Because thymoma is a rare tumor, the
sample size could not be statistically based and the study
terminated after inclusion of 18 patients. Eligibility criteria
were as follow histologically proven thymoma or thymic
carcinoma with extensive disease. Lymphomas of the thymus
were excluded. Review of pathology slides was performed by
two experimented pathologists. Patients should have an un-
resectable tumor. Patients with previous radiotherapy were
eligible if distant metastases were present or if there was
documented progressive disease at the site of previous radio-
therapy. For all patients, there was at least one bidimension-
ally measurable lesion with baseline measurements per-
formed within 4 weeks before study entry.
Patients were required to have an ECOG performance
status less than or equal to two, adequate hepatic function
(serum bilirubin 2 mg/dL), adequate renal function (creat-
inine 1.5 times to upper limit of normal or calculated
creatinin clearance50 mL/min), and a bone marrow reserve
(white blood cell count 4000/mm3 and platelet count
120,000/mm3). Patients had no previous chemotherapy or
any previous malignancy within the previous 5 years, except
basal cell carcinoma of the skin or carcinoma in situ of the
breast or cervix. Cardiac function was compatible with hy-
dratation. All patients were older than 18 years and provided
written informed consent. The study was approved by the
Institutional Review Board.
Pretreatment evaluation included a history and phys-
ical examination, a chest radiograph, complete blood
count, serum electrolytes, chemistry panel, and serum
creatinin level with systematic measurement of creatinine
clearance. Computed tomography (CT) scan of the chest
and abdomen were performed as indicated for tumor mea-
surements. During the treatment, history and physical
examinations, serum chemistry panels, complete blood
counts, and radiographs were performed every 3 weeks.
CT scans were performed as indicated within 4 weeks.
After treatment, patients were observed with history and
physical examinations, with CT scan of the chest and
abdomen every 3 months the first year, every 4 months the
second year, and every 6 months thereafter.
Treatment Plan
After intravenous hydratation with normal saline, pa-
tients received subsequently cisplatin 30 mg/m2 on days 1–3,
etoposide 100 mg/m2 on days 1–3, ifosfamide 1500 mg/m2 on
days 1–3, and methylprednisolone 80 mg on days 1–3. In
addition, mesna was administered at 500 mg/m2 before ifos-
famide and 5 hours and 8 hours later on days 1–3. Granulo-
cyte colony-stimulating factor was given on days 4–14 only
in case of febrile neutropenia after the first course. Cycles
were repeated every 21 days. The number of courses was as
follows:
In the neoadjuvant setting, three cycles were delivered in
patients with OR (stable disease excluded), followed by
radiotherapy or surgery according to the staging.
In the metastatic or recurrence setting, six courses were
delivered in patients with OR, stable disease included.
Patients with tumor progression were taken off study. Pa-
tients were initially evaluated for response after two cycles.
A CR was defined as the complete disappearance of all
objective evidence of disease lasting at least 1 month. A
PR was defined as a reduction 50% in the sum of the
products of perpendicular greatest dimensions of all mea-
sured lesions lasting at least 1 month. Survival duration
was measured from the time of inclusion until the date of
death. Response duration was measured from the date
of the first documented response until disease recurrence or
death. Treatment failure was defined as the first event
disease progression, recurrence after response, or death.
Survival distribution for overall survival time was esti-
mated with the method of Kaplan and Meier.12 The exact
binomial CIs were computed using the methodology of
Woolson.13
RESULTS
Patient Characteristics
Patient characteristics are listed in Table 1. Eight-
een patients were registered on the trial. Two patients were
excluded from analysis because pathologic examination
revealed improper histology (one patient with lymphoma,
one patient with small cell carcinoma) leaving 16 patients
who were eligible and evaluable, including 10 males and
six females. Fourteen patients were whites, two patients
were Africans. The median age of patients was 51 years
(range, 35–73 years).
Twelve percent of the patients had an ECOG perfor-
mance status of 0, 68, and 20% of the patients had a
performance status of 1 and 2, respectively. No patient had
undergone previous surgery or received previous radiother-
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apy. Twelve patients (75%) had thymoma and four patients
(25%) had thymic carcinoma. Among thymoma patients, five
B3 World Health Organization histologic types were regis-
tered. The most frequent sites of metastases were the pleura
(66%) and the pericardium (46%). One patient had metasta-
ses to the liver and one patient to the bone. No patients had
brain or skin metastases.
A total of 49 cycles of chemotherapy were administered
to the 16 eligible patients, with an average number of three
cycles. Only one patient received six cycles. The median
follow-up was 32.6 months (range, 9–84 months).
Toxicity
Toxicity was graded according to the World Health
Organization criteria. All 18 entered patients were evaluable
for toxicity. Table 2 lists the grades 3 and 4 toxicities. The
majority of grades 3 and 4 toxicities were hematologic or
related to alopecia. Ten episodes of grade 4 hematologic
toxicities occurred in six patients on the study. There was no
death associated with hematologic toxicity. There was one
patient with grade 4 emesis, one patient with pulmonary
toxicity, and one patient with hemorrhagic toxicity. No pa-
tients had cardiac toxicity.
Response and Survival
Among the 16 evaluable patients, four PR and no CR
were observed. Twelve patients had stable disease, and no
patients had progressive disease. The overall objective re-
sponse rate was 25% (95% CI, 7–43%). At the end of the
follow-up, one of the responders had CR, one had progressed
and two were dead. The median response duration was 13.1
months (range, 3–28 months). Among the four patients
with thymic carcinoma, one demonstrated a PR to therapy
and three had a stable disease. We did not observe differences
in objective response rates as related to age (55 years versus
55 years: 27% versus 21%); nevertheless males achieved a
higher but non significant response rate as compared with
females (male versus female: 30% versus 16.7%, p  0.31).
Regarding survival, among the 16 evaluable patients,
11 patients were alive at the time of this analysis, with
survival times of 10 to 65 months. Based on the Kaplan-
Meier method, the estimated 1-year, 2-year, and 3-year
survival rates for all patients are 93.8, 78.1, and 58.6%,
respectively.
Two of the four patients with thymic carcinoma have
died to date. Six patients (one thymic carcinoma and five
thymoma) have been operated after induction chemotherapy:
no complete histologic responses were observed. After sur-
gery, six of these 11 patients have been treated by radiother-
apy. Five of them were alive at the end of the follow-up.
DISCUSSION
Epithelial thymic tumor is a unique neoplasm that
frequently is associated with indolent growth and a variety of
paraneoplastic syndromes. Their natural history is diverse,
ranging from localized and indolent tumors to diseases with
aggressive and widespread metastasis. For patients with lo-
calized thymoma or thymic carcinoma, surgery and/or radio-
therapy is usually the treatment of choice.14 More recently,
several prospective trials have demonstrated chemosensitivity
for thymoma and, to a lesser degree, to thymic carcinoma. To
TABLE 1. Patient Characteristics (n  16 Patients)
Characteristic
No. of
Patients (%)
Age (yrs)
Median 51
Range 35–73
Male:female 10:6
Caucasian:black 14:2
Performance status
0 2 (12)
1 11 (69)
2 3 (19)
Weight loss
5% 9 (56)
5–10% 5 (31)
10% 2 (12)
Metastatic sites
Pleura 10 (62)
Lung 5 (31)
Liver 1 (06)
Bone 1 (06)
Mediastinal only 2 (12)
Other 7 (44)
Histology (WHO 1999)
Thymoma 12 (75)
Type A 0 (0)
Type AB 2 (12)
Type B1 3 (19)
Type B2 2 (12)
Type B3 5 (31)
Thymic carcinoma ( C type) 4 (25)
Masaoka staging
III B 8 (50)
IV A 1 (06)
IV B 7 (44)
TABLE 2. Incidence of Grades 3–4 Toxicity (N  18 Patients)
CTC Grade
Type 3 4
Leukopenia 3 3
Thrombocytopenia 2 5
Anemia 5 2
Hemorrhage 1 0
Infection 2 0
Nausea 4 0
Emesis 0 1
Diarrhea 1 0
Pulmonary 1 1
Alopecia 17 0
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date, the most commonly reported chemotherapeutic combi-
nation for thymoma includes both cisplatin and doxorubicin.
The objective responses rates of such regimens have ranged
from 50 to 92% (Table 3). The development of nonanthra-
cycline-based chemotherapy regimens is appealing when
considering concurrent or sequential radiotherapy as part of
the treatment strategy. Cisplatin plus etoposide was reported
to produce a 50% objective response rate in patients with
advanced thymoma and was suggested as a good alternative
to doxorubicin-based combinations.8 In this trial, the VIP
regimen demonstrated an overall response rate of only 25%,
lower than the 32% of the ECOG trial, which was the worst
objective response rate in 2001.11 Nevertheless, the 2-year
survival seems to be similar to that in others trials.
Although the rarity of thymic neoplasm precludes
randomized trials to compare regimens, these data com-
pare unfavorably with previously reported trials, excepted
the ECOG’s one. No obvious differences in response rates
were noted when examining age, performance status, or
weight loss.
Table 3 summarizes our results as compared with other
combinations, which seem to be superior to this trial.15–21 The
modest decrease in the total dose of etoposide (from 360
mg/m2 to 300 mg/m2) compared with the European Organi-
zation for Research in the Treatment of Cancer trial seems an
unlikely factor. The most likely explanation is that the patient
population and sample sizes of these trials have overlapping
CIs. The patient population in the current study contained a
much greater proportion of patients with thymic carcinoma
(25%) than the previously published series. Indeed, in many
previous trials, patients with thymic carcinoma have been
excluded from the trials.
Although more follow-up is required, this trial suggests
that there is an inferior response rate for the VIP regimen in
patients with thymic neoplasm compared with previous trials
using the PAC or etoposide  cisplatine regimens, but the
2-year survival seems to be similar. The current trial confirms
the ECOG study published in 2001.
The main limit of our study is a small number of
included patients, because thymic carcinoma are rare tumors.
It is also difficult to compare our data to other historic series.
More so there is no control group, which seems to be only
possible in multicentric studies.
CONCLUSION
The VIP regimen seems to have moderate activity in
terms of response rate, in the treatment of patients with
advanced thymoma or thymic carcinoma with a response rate
around 30%. Concurrently, all series using cisplatin plus
doxorubicin regimens seem somewhat superior with response
rates more than 50%. Nevertheless, the VIP regimen can be
an alternative therapy in case of contraindication to the use of
doxorubicin. All this results proceed from small series, so it
is necessary to enroll patients on prospective trials to confirm
these data and better define new therapeutic strategies.
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